Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of locally advanced or metastatic melanoma.
Melanoma
DRUG: Cadonilimab|DRUG: anlotinib
Response Rate, ORR is the proportion of patients with best response of complete response (CR) and PR, from the frst drug administration up to two years
Progression-free Survival (PFS), Time from the date of frst study treatment administration to the date of first, from the frst drug administration up to two years|Disease Control Rate (DCR), Proportion of patients whose best overall response is either CR, PR, or SD, from the frst drug administration up to two years|Safety and tolerability, Incidence, nature, and severity of adverse events graded according to the NCI CTCAE, from the frst drug administration up to two years
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of locally advanced or metastatic melanoma.